Abstract：
Mesenchymal-epithelial transition factor (MET) has long been considered as the most crucial and promising driver gene in the occurrence and development of non-small cell lung cancer (NSCLC), except for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ROS oncogene 1 receptor tyrosine kinase (ROS1). In recent years, therapeutic drugs targeting MET have been continuously developed and applied in clinical practice. First, the curative effect of NSCLC patients with MET exon 14 skipping mutations has been further improved. In addition, when MET amplification occurs after resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced EGFR-mutant NSCLC, the combination of MET-TKIs and EGFR-TKIs has brought significant survival benefits and many other advances. This article reviews the treatment progress of NSCLC patients with different types of MET variants under different circumstances, which provides reference for the selection of clinical treatment strategies.
.
【中文题目：合并MET基因变异的非小细胞肺癌治疗 研究进展】 【中文摘要：间质-上皮细胞转化因子（mesenchymal-epithelial transition factor, MET）长期以来被认为是非小细胞肺癌（non-small cell lung cancer, NSCLC）发生发展过程中除表皮生长因子受体（epidermal growth factor receptor, EGFR）、间变性淋巴瘤激酶（anaplastic lymphoma kinase, ALK）、原癌基因酪氨酸蛋白激酶（c-ros oncogene 1 receptor tyrosine kinase, ROS1）之外最重要和最有前景的驱动基因。近年来，靶向MET的治疗药物不断被研发并应用于临床。首先是合并MET外显子14跳跃突变的NSCLC患者疗效得到进一步的提高。另外，晚期EGFR突变型NSCLC患者EGFR酪氨酸激酶受体抑制剂（EGFR tyrosine kinase inhibitors, EGFR-TKIs）耐药后继发MET扩增时，联合MET-TKIs和EGFR-TKIs的方案带来了明显的生存获益等诸多进展。本文综述了在不同情况下，NSCLC患者合并MET不同变异类型的治疗进展，为临床治疗策略的选择提供参考。 】 【中文关键词：肺肿瘤；MET扩增；跳跃突变；MET酪氨酸激酶抑制剂】.
【中文题目：合并MET基因变异的非小细胞肺癌治疗 研究进展】 【中文摘要：间质-上皮细胞转化因子（mesenchymal-epithelial transition factor, MET）长期以来被认为是非小细胞肺癌（non-small cell lung cancer, NSCLC）发生发展过程中除表皮生长因子受体（epidermal growth factor receptor, EGFR）、间变性淋巴瘤激酶（anaplastic lymphoma kinase, ALK）、原癌基因酪氨酸蛋白激酶（c-ros oncogene 1 receptor tyrosine kinase, ROS1）之外最重要和最有前景的驱动基因。近年来，靶向MET的治疗药物不断被研发并应用于临床。首先是合并MET外显子14跳跃突变的NSCLC患者疗效得到进一步的提高。另外，晚期EGFR突变型NSCLC患者EGFR酪氨酸激酶受体抑制剂（EGFR tyrosine kinase inhibitors, EGFR-TKIs）耐药后继发MET扩增时，联合MET-TKIs和EGFR-TKIs的方案带来了明显的生存获益等诸多进展。本文综述了在不同情况下，NSCLC患者合并MET不同变异类型的治疗进展，为临床治疗策略的选择提供参考。 】 【中文关键词：肺肿瘤；MET扩增；跳跃突变；MET酪氨酸激酶抑制剂】.
摘要：
暂无翻译
